Caffeine and adenosine A2A receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease

Annals of Neurology

Volumn 73, Issue 5, 2013, Pages 655-666

  Gonçalves, Nélio ^a,b   Simões, Ana T ^a,b   Cunha, Rodrigo A ^a,c   De Almeida, Luís Pereira ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; ATAXIN 1; CAFFEINE; CD11B ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; LENTIVIRUS VECTOR; MICROTUBULE ASSOCIATED PROTEIN 2; PHOSPHOPROTEIN DARPP 32; POLYGLUTAMINE; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTOSIS; BASAL GANGLION; CAG REPEAT; CONTROLLED STUDY; GLIOSIS; HEMISPHERE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MACHADO JOSEPH DISEASE; MALE; MOUSE; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD11B; CAFFEINE; CELL DEATH; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; GENE EXPRESSION REGULATION; GENETIC VECTORS; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTRANUCLEAR INCLUSION BODIES; LENTIVIRUS; MACHADO-JOSEPH DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NERVE TISSUE PROTEINS; NEUROGLIA; NUCLEAR PROTEINS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTOR, ADENOSINE A2A; REPRESSOR PROTEINS; SYNAPTOPHYSIN; TIME FACTORS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84878306815     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23866     Document Type: Article

References (79)

1. Koshy BT, Zoghbi HY,. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Brain Pathol 1997; 7: 927-942.
2. Ranum LP, Lundgren JK, Schut LJ, et al. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am J Hum Genet 1995; 57: 603-608.
3. Durr A, Stevanin G, Cancel G, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996; 39: 490-499.
4. Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8: 221-228.
5. Gwinn-Hardy K, Singleton A, O'Suilleabhain P, et al. Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family. Arch Neurol 2001; 58: 296-299.
6. Taroni F, DiDonato S,. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci 2004; 5: 641-655.
7. Sudarsky L, Coutinho P,. Machado-Joseph disease. Clin Neurosci 1995; 3: 17-22.
8. Alves S, Regulier E, Nascimento-Ferreira I, et al. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum Mol Genet 2008; 17: 2071-2083.
9. Klockgether T, Skalej M, Wedekind D, et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 1998; 121: 1687-1693.
10. Taniwaki T, Sakai T, Kobayashi T, et al. Positron emission tomography (PET) in Machado-Joseph disease. J Neurol Sci 1997; 145: 63-67.
11. Wullner U, Reimold M, Abele M, et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol 2005; 62: 1280-1285.
12. Paulson HL, Perez MK, Trottier Y, et al. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997; 19: 333-344.
13. Bichelmeier U, Schmidt T, Hubener J, et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 2007; 27: 7418-7428.
14. Goti D, Katzen SM, Mez J, et al. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J Neurosci 2004; 24: 10266-10279.
15. Cemal CK, Carroll CJ, Lawrence L, et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 2002; 11: 1075-1094.
16. Andrews TC, Weeks RA, Turjanski N, et al. Huntington's disease progression. PET and clinical observations. Brain 1999; 122: 2353-2363.
17. Li H, Li SH, Yu ZX, et al. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci 2001; 21: 8473-8481.
18. Bantubungi K, Jacquard C, Greco A, et al. Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis 2005; 18: 206-217.
19. Aktas O, Smorodchenko A, Brocke S, et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 2005; 46: 421-432.
20. Gao HM, Kotzbauer PT, Uryu K, et al. Neuroinflammation and oxidation/nitration of α-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008; 28: 7687-7698.
21. Lee JW, Lee YK, Yuk DY, et al. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation 2008; 5: 37.
22. Cunha RA, Agostinho PM,. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis 2010; 20 (suppl 1): S95-S116.
23. 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 2007; 83: 310-331.
24. Gomes CV, Kaster MP, Tome AR, et al. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta 2011; 1808: 1380-1399.
25. 2A receptors in Huntington's disease. Prog Neurobiol 2007; 81: 331-348.
26. Koch P, Breuer P, Peitz M, et al. Excitation-induced ataxin-3 aggregation in neurons from patients with Machado-Joseph disease. Nature 2011; 480: 543-546.
27. Simões AT, Gonçalves N, Koeppen A, et al. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin-3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. Brain 2012; 135: 2428-2439.
28. 2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999; 19: 9192-9200.
29. Duarte JM, Agostinho PM, Carvalho RA, Cunha RA,. Caffeine consumption prevents diabetes-induced memory impairment and synaptotoxicity in the hippocampus of NONcZNO10/LTJ mice. PLoS One 2012; 7: e21899.
30. Costenla AR, Cunha RA, de Mendonca A,. Caffeine, adenosine receptors, and synaptic plasticity. J Alzheimers Dis 2010; 20 (suppl 1): S25-S34.
31. Duarte JM, Carvalho RA, Cunha RA, Gruetter R,. Caffeine consumption attenuates neurochemical modifications in the hippocampus of streptozotocin-induced diabetic rats. J Neurochem 2009; 111: 368-379.
32. de Almeida LP, Zala D, Aebischer P, Deglon N,. Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiol Dis 2001; 8: 433-446.
33. Yen TC, Tzen KY, Chen MC, et al. Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers. J Nucl Med 2002; 43: 153-159.
34. de Almeida LP, Ross CA, Zala D, et al. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002; 22: 3473-3483.
35. Cyr M, Beaulieu JM, Laakso A, et al. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A 2003; 100: 11035-11040.
36. Coleman P, Federoff H, Kurlan R,. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004; 63: 1155-1162.
37. 2A receptors in the hippocampus and striatum of the rat. Neuroscience 2005; 132: 893-903.
38. D'Abreu A, Franca M Jr, Appenzeller S, et al. Axonal dysfunction in the deep white matter in Machado-Joseph disease. J Neuroimaging 2009; 19: 9-12.
39. Seidel K, den Dunnen WF, Schultz C, et al. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol 2010; 120: 449-460.
40. Chou AH, Chen SY, Yeh TH, et al. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol Dis 2011; 41: 481-488.
41. DiProspero NA, Chen EY, Charles V, et al. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol 2004; 33: 517-533.
42. Smith R, Klein P, Koc-Schmitz Y, et al. Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease. J Neurochem 2007; 103: 115-123.
43. Li JY, Plomann M, Brundin P,. Huntington's disease: a synaptopathy? Trends Mol Med 2003; 9: 414-420.
44. Wishart TM, Parson SH, Gillingwater TH,. Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol 2006; 65: 733-739.
45. Trottier Y, Cancel G, An-Gourfinkel I, et al. Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol Dis 1998; 5: 335-347.
46. Horimoto Y, Matsumoto M, Akatsu H, et al. Longitudinal study on MRI intensity changes of Machado-Joseph disease: correlation between MRI findings and neuropathological changes. J Neurol 2011; 258: 1657-1664.
47. Silva-Fernandes A, Costa Mdo C, Duarte-Silva S, et al. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol Dis 2010; 40: 163-176.
48. Evert BO, Vogt IR, Kindermann C, et al. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains. J Neurosci 2001; 21: 5389-5396.
49. Lobsiger CS, Cleveland DW,. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007; 10: 1355-1360.
50. Wang G, Ide K, Nukina N, et al. Machado-Joseph disease gene product identified in lymphocytes and brain. Biochem Biophys Res Commun 1997; 233: 476-479.
51. Fredholm BB, Battig K, Holmen J, et al. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
52. Ferré S,. An update on the mechanisms of the psychostimulant effects of caffeine. J Neurochem 2008; 105: 1067-1079.
53. 2A receptors in Parkinson's disease. Trends Neurosci 2006; 29: 647-654.
54. 2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci 2009; 29: 14741-14751.
55. 2A receptors prevents staurosporine-induced apoptosis of rat hippocampal neurons. Neurobiol Dis 2007; 27: 182-189.
56. 2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia 2003; 43: 190-194.
57. 2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol 2007; 66: 363-371.
58. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 2008; 63: 338-346.
59. 2A receptors control neuroinflammation and consequent hippocampal neuronal dysfunction. J Neurochem 2011; 117: 100-111.
60. 2A receptors and basal ganglia physiology. Prog Neurobiol 2007; 83: 277-292.
61. 2A receptor blockade. Purinergic Signal 2005; 1: 111-134.
62. Arrasate M, Mitra S, Schweitzer ES, et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431: 805-810.
63. Saudou F, Finkbeiner S, Devys D, Greenberg ME,. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95: 55-66.
64. Takahashi T, Kikuchi S, Katada S, et al. Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. Hum Mol Genet 2008; 17: 345-356.
65. Taylor JP, Tanaka F, Robitschek J, et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 2003; 12: 749-757.
66. Burnett B, Li F, Pittman RN,. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet 2003; 12: 3195-3205.
67. Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K,. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol 2003; 23: 6469-6483.
68. Kuhlbrodt K, Janiesch PC, Kevei E, et al. The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat Cell Biol 2011; 13: 273-281.
69. Warrick JM, Morabito LM, Bilen J, et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell 2005; 18: 37-48.
70. Cajigas IJ, Will T, Schuman EM,. Protein homeostasis and synaptic plasticity. EMBO J 2010; 29: 2746-2752.
71. DiAntonio A, Hicke L,. Ubiquitin-dependent regulation of the synapse. Annu Rev Neurosci 2004; 27: 223-246.
72. Jiang X, Litkowski PE, Taylor AA, et al. A role for the ubiquitin-proteasome system in activity-dependent presynaptic silencing. J Neurosci 2010; 30: 1798-1809.
73. Rinetti GV, Schweizer FE,. Ubiquitination acutely regulates presynaptic neurotransmitter release in mammalian neurons. J Neurosci 2010; 30: 3157-3166.
74. Wang J, Wang CE, Orr A, et al. Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice. J Cell Biol 2008; 180: 1177-1189.
75. 2A receptor. Mol Pharmacol 2006; 69: 1083-1094.
76. 2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system. Hum Mol Genet 2009; 18: 2929-2942.
77. 2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 2008; 57: 121-134.
78. 2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia 2012; 60: 702-716.
79. 2A adenosine receptors. Glia 2002; 39: 133-147.